Comparison of Low-Dose Rosuvastatin with Atorvastatin in Lipid-Lowering Efficacy and Safety in a High-Risk Pakistani Cohort: An Open-Label Randomized Trial

Table 1

Baseline characteristics of study population.

Variable	Atorvastatin group; (𝑛=63)	Rosuvastatin group; (𝑛=66)	P value
Age (years)	54.10±12.66	55.44±9.43	0.494
Gender (M : F)	34 : 29	26 : 40	0.097*
Education (years)	5.24±3.63	3.70±3.75	0.019
Current smokers	10 (15.87%)	3 (0.04%)	0.028*
BMI (kg/m^2)	25.63±3.66	27.61±4.88	0.011
Waist circumference (cm)	94.49±8.25	100.17±9.87	0.001
Serum total cholesterol	4.92±0.906	5.04±0.91	0.447
Serum triglycerides	2.21±1.10	1.99±0.97	0.216
Serum HDL-C	0.9876±0.20	1.20±0.93	0.071
Serum LDL-C	2.91±0.86	3.19±0.92	0.074

∗By chi-square test; all other P values were calculated by independent samples t-test.